During the quarter, EBITDA stood at Rs 3,939 crore (including other operating revenues), up 23.9%, with resulting EBITDA margin of 29.6%

Sales of Formulation in India for Q2 FY25 were at Rs 4,265.2 crore, up 11% YoY and accounting for approximately 32% of total consolidated sales.

US Formulation sales were $517 million in Q2 FY25, up 20.3% YoY and accounting for approximately 33% of total consolidated sales.

Formulation sales in Emerging markets were $293 million for Q2 FY25, growing by 3.2% YoY and accounted for approximately 18% of total consolidated sales.

Formulation sales in rest of world (ROW) markets were $190 million in Q1 FY25, down 2.9% and accounted for 12.6% of total consolidated sales.

In Q2 FY25, formulation sales in the Rest of World (ROW) markets, excluding India, the US, and Emerging Markets, reached $199 million. This reflects a 3.5% decline compared to Q2 of the previous year and accounting for approximately 13% of total consolidated sales.

During the quarter, external sales of API stood at Rs 533.8 crore, up 7.4% YoY. The company said that it continue to focus on increasing API supply for captive consumption for key products.

Consolidated R&D investment was at Rs 792.9 crore for Q2 FY25 or 6% of sales as compared to Rs 773.4 crore for Q2 FY24.

On half year basis the company’s consolidated net profit jumped 33.59% to Rs 5,875.78 crore in H1 FY25 as against Rs 4,398.05 crore posted in H1 FY24. The company’s revenue from operation increased 7.50% YoY to Rs 25,944.14 crore in H1 FY25.

The company stated that its R&D efforts encompass both specialty and generic businesses, with ongoing investments aimed at building a pipeline for various markets, including the US, Emerging Markets, Rest of World (RoW) Markets, and India. It reported having seven molecules in clinical trials within their specialty R&D pipeline. The company highlighted a comprehensive product offering in the US market, which includes approved Abbreviated New Drug Applications (ANDAs) for 538 products, while filings for 105 ANDAs are pending US FDA approvals, including 28 with tentative approvals. Additionally, the firm mentioned 51 approved New Drug Applications (NDAs), with 13 NDAs awaiting US FDA approval. For the quarter, it filed three ANDAs and received approval for one ANDA, as well as one NDA approval.

Dilip Shanghvi, chairman and MD, said, “Sun has recently strengthened its specialty pipeline through an agreement with Philogen for commercializing late stage candidate Fibromun, upon approval. With Fibromun, our product basket for dermatologists has expanded further. We shall continue to leverage our strong cash position to strengthen our pipeline with products that are close to market.”

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with specialty and generic presence and India's top pharma company.